Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug,
 telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Inclusion Criteria:

 -  Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours
 of continuous stay in an inpatient acute or chronic care facility or acquired within 7
 days after being discharged from a hospitalization of greater than or equal to 3 days
 duration.

 Exclusion Criteria:

 -  Received more than 24 hours of potentially effective systemic (IV, IM or PO)
 antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.